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The most common genetic cardiomyopathy, HCM, has a prevalence of about 0.2%. It is inheritance pattern with 
the autosomal dominant transmission. The natural history is benign but adverse outcomes can happen in some 
patients including sudden cardiac death, symptoms due to dynamic obstruction of the outflow tract of the left 
ventricular (LVOT), abnormal diastolic filling, atrial fibrillation, and dysfunction of systolic LV.
Imaging modalities can be used to evaluate the structure and function of the heart, the dynamic obstruction and 
its severity, mitral valve abnormalities, regurgitation of the mitral valve, and also myocardial ischemia and 
fibrosis. Echocardiography is the first imaging modality for cardiac structure evaluation. CMR is recommended 
when echocardiographic images are not adequate in patients with high suspicion for HCM. In the case of 
contraindication to CMR, patients with ICDs or pacemakers, Cardiac CT is recommended. Imaging can be used to 
screening, preclinical diagnosis and treatment guidance in a patient with HCM.
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 Hypertrophic cardiomyopathy (HCM) is the genetic cardio-
myopathy that can be divided into two categories, hypertrophic 
obstructive cardiomyopathy (HOCM) and hypertrophic non-obstructive 
cardiomyopathy (HNCM). Prevalence of HCM is 1:500 in the general 
population. It is an autosomal dominant disease caused by over 1,400 
mutations in at least 11 genes encoding proteins of the cardiac 
sarcomere.1 Although the majority of patients with HCM is asymptom-
atic, subset remains at risk for having sudden death. The rate of mortal-
ity of HCM in the general population ranges <1% until 3-6% in tertiary 
referral centres.2
 HCM management is based on an understanding of its anatomy and 
pathophysiology. It is highly dependent on accurate non-invasive 
examination. A careful examination to see the presence of other 
structural heart diseases by imaging is crucial to do a systematic evalua-
tion of the structure and function of the heart in terms of proper patient 
selection for further therapy.
2. Definition 
 HCM is cardiomyopathy marked by global or asymmetric 
cardiac hypertrophy, that is not caused by chronic overpressure  
Important microscopic features of this disorder are the occurrence of 
extensive myocardial hypertrophy, myofiber disarray and fibrosis.3
3. Epidemiology
 Prevalence of HCM vary between 1:500 (0.2%) and 1:3,000 
(0.03%) in studies at North America, Europe, Asia and Africa.3 In the 
2015 prevalence study in Germany, HCM occurred in 4,000 of 
5,490,810 patients (0.07%; 1: 1,372). The prevalence of HCM increas-
ing with age from 7.4/100,000 people at the age of 0-9 years to 
298.7/100,000 people in patients aged >80 years. Men have a higher 
prevalence, especially in patients >30 years of age.4
4. Pathogenesis and Pathophysiology
 The pathogenesis of HCM is due to the presence of mutated 
genes responsible for producing sarcomere complex proteins including 
heavy-chain beta myosin protein, troponin, and myosin-binding protein 
C, which will result in impaired contraction of heart muscle.5 
The pathophysiology of HCM can be divided into:
(1) Echocardiography
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 Two-dimensional (2D) echocardiographic criteria diagnosis 
of HCM:7-9
• Maximal thickness of LV wall >15 mm in any segment myocardial, 
measured by echocardiography, CMR or computed tomography CT), 
which cannot be explained only by changing loading conditions, or
• >12-15 mm in relatives,
• ≥2 SD greater than the normal body-surface in pediatric patients
• The thickness ratio of septal and posterior wall > 1.3 in normotensive 
patients, or > 1.5 in hypertensive patients
 The distribution of hypertrophy can occur in various forms, 
locations, and includes the right ventricle. In patients suspected as 
HCM, all LV segments from the base to the apical must be examined, to 
ensure the thickness of the wall (Figure 1).3,7,8
 
 
Figure 1. (A) Apical 4C position, LVH with diffuse massive hypertrophy; 
(B) short-axis view, at the level of PMs; (C) ASH in long-axis view (D) 
Apical 4C view with apical wall thickness 15 mm. (E) Ace of spade 
configuration in apical HCM (F) LV cavity opacification with contrast.8
 One of an atypical form of HCM is apical HCM/ApHCM, also 
known as Yamaguchi syndrome, presenting exertional chest pain and 
dyspnea mimicking acute coronary syndrome.10,11 ApHCM is marked by 
giant negative T-waves on precordial lead ECG but no ST-T changes 
and spade-like configuration of LV cavity in end-diastole on echocardio-
gram.12,13 Predominant LVH in the LV apex wall with ≥ 15mm 
thickness. Typically, there is no LVOT obstruction in ApHCM, from 
SAM and no mitral regurgitation. However, it can coincide with 
obstruction of the midventricular wall and LV cavity obliteration 
(MVOCO), and formation of an apical aneurysm.13
 
 There are three forms of ApHCM: (1) “pure”, isolated apical 
hypertrophy; (2) “mixed”, both apical and septal hypertrophy with the 
apex thickest; and (3) “relative” ApHCM, an early ApHCM phenotype 
that can be detected by CMR.13
 Transthoracic Echocardiography (TTE) with contrast agent 
should be considered in patients with suspicion of apical HCM, to 
determine the extent of hypertrophy, diagnosing apical aneurysm and 
clots.14,15 Echocardiography 3D can accurately calculate the LV mass 
with adequate image quality and experienced operators.14 
 Left ventricle EF is generally normal in patients with HCM. 
LV systolic dysfunction in HCM, referred to as "dilated or progressive 
phase of HCM", "end-stage HCM", "burnt-out HCM", with EF <50% and 
only occur in a small proportion of patients (2% - 5%).9.14
 Subclinical LV systolic dysfunction can be assessed by the 
velocity of myocardial movement in the systolic and diastolic phases. 
Decreased systolic velocity (Sa) and initial phase diastolic velocity (Ea 
or e’) can occur before the significant onset of hypertrophy. Imaging to 
determine the strain rate is useful distinguishing non-obstructive HCM 
from hypertensive LV hypertrophy. Speckle-tracking echocardiography 
(STE) assess myocardial motion directly through 2D images which 
shows a decrease in strain on HCM (Figure 2).16
Figure 2. The global LV strain was reduced by 7% in patients with HCM 
(left). Radial strains were significantly reduced in six segments 
(right).14
 Diastolic abnormalities in HCM can be assessed with Dopler 
echocardiography. A study showed in HCM patients, an association 
between impaired severe LV relaxation and a significant decrease in 
annular velocities. The size of the LA provides prognostic information 
on HCM. The increase of LA size is multifactorial, with significant 
contributions from the severity of mitral regurgitation, the occurrence 
of diastolic dysfunction, and the possibility of atrial myopathy.7
 LVOT obstruction is defined as an increase of gradient of the 
LVOT ≥30 mmHg at rest or during the physiological provocations such 
as the manoeuvre of Valsalva, standing and exercise. Gradients ≥50 
mmHg is the threshold at which LVOT obstruction becomes hemody-
namically important. In the dynamic obstructive HCM, there is an 
appearance of a late-peaking dagger-shaped (Figure 3).16 Administering 
amylnitrite, upright exercise, or the manoeuvre of Valsalva in symptom-
atic patients with gradients at rest <30 mm Hg should be pursued to 
provoke hemodynamic obstruction. It is essential to exclude that 
obstruction is not associated with SAM, such as obstruction of LV mid 
cavity, membrane sub-aortic abnormality of the mitral valve, especially 
when considering interventions to reduce the LVOT obstruction.3
 Abnormalities of the apparatus of the mitral valve include 
hypertrophied papillary muscles, which causes an anterior shift of 
papillary muscles and mitral valve elongation. It causes the valve tends 
to be pushed into the LVOT forming systolic anterior motion (SAM), as 
a characteristic of obstructive HCM.17 SAM will cause turbulent flow, 
seen as a mosaic pattern with colour Doppler that can cause uncoapta-
tion of the mitral leaflet, and led to the mitral regurgitation (Figure 4).14
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(N)-labeled ammonia or 15-oxygen (O)-labeled water, evaluation of 
perfusion in the transmural (subepicardial and subendocardial) can be 
performed.18
 In normal coronary arteries, the study PET myocardial 
perfusion has shown that there is significantly reduced the augmenta-
tion of blood flow in the subendocardial region by vasodilatation (eg., 
Dipyridamole), despite the resting myocardial blood flow, in 
millilitres/gram/minute, probably the same with the normal control.18
Figure 5. Evaluation of myocardial ischemia in HCM using 201Thallium 
SPECT.
(A, B) shows severe asymmetric septal hypertrophy at short-axis and 4C 
position. Multidetector CT shows no atherosclerosis of the LAD (C), LCx 
(D), and RCA (E). Stress-induced perfusion defects in the septum and 
inferior wall, and transient LV dilatation at short-axis slices of 201Tl 
SPECT (F), which normalize at rest (G). It suggest extensive subendo- 
cardial ischemia, without obstructive major epicardial coronary 
arteries.18 
Figure 6. Rest (A) and Stress (B) perfusion mapping in ApHCM.13
(3) Cardiovascular Magnetic Resonance (CMR) 
 Tomographic imaging technique with a high-resolution 3D, 
CMR gives a sharp contrast between the myocardium and blood pool. It 
has emerged as an imaging technique to characterize the morphologi-
cal of HCM.  The imaging choice when the diagnosis of HCM still 
unclear after echocardiography. Contrast-enhanced CMR with late-gad-
olinium enhancement (LGE) can identify areas of scarring or myocardi-
al fibrosis.19
 Imaging CMR produces multiple slices of myocardial thin 
(thickness 7 mm) on the short axis view provides coverage tomography 
entire myocardium and the measurement of wall thickness accuracy 
and volume and ventricular mass (Figure 7).20
The number and papillary muscle mass were also increased in HCM. In 
addition, a small portion of patients with HCM have a focal LV 
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Figure 3. Continuous-wave Doppler (CW), concave contours, peak 
velocity of LVOT (4.5 m/sec) (left) and a top speed signal mitral 
regurgitation (6.3 m / sec) (right). Identification of these contours can 
be useful to distinguish high CW jet of the dynamic obstruction of LVOT 
and mitral regurgitation from aortic valve stenosis.14 
Figure 4. SAM M-mode recording and contact septal mitral leaflet 
(arrow) (left). 2D echocardiography view of SAM (arrow) (right). 
Color Doppler showed a high speed across the LVOT in a mosaic 
pattern and eccentric mitral regurgitation jet.14
(2) Nuclear Imaging
 Assessing the systolic and diastolic function of the LV in HCM 
patients can be performed with nuclear imaging techniques.  It is also 
used to assess myocardial ischemia (microvascular dysfunction using 
positron emission tomography or PET).18
• SPECT (Single Photon Emission Computed Tomography)
 In the absence of epicardial coronary artery stenosis,  
ischemia in patients with HCM can be caused by disease of the small 
blood vessels intramural, massive hypertrophy, and abnormal microcir-
culation which causes myocardial blood flow is inadequate, especially 
if myocardial oxygen demand increased such as the presence of LV 
hypertrophy and obstruction of the outflow tract.18
 SPECT perfusion imaging using 201 Tl or 99m Tc sestamibi 
or tetrofosmin, may show fixed defects or reversible perfusion or mix 
defects. Stress-induced reversible perfusion defects reflect ischemia of 
myocardium and are frequently observed in patients with good LV 
function (Figure 5).18 
 The perfusion map of ApHCM showed ‘solar polar” on 
SPECT. Bright apical spot surrounded by a circumferential ring of 
decreasing counts (Figure 6).13
• Positron Emission Tomography (Positron Emission Tomography / 
PET)
 PET has a higher spatial resolution than SPECT that allows 
quantification of myocardial blood flow. Using tracers of 13-nitrogen
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LV hypertrophy (with normal LV mass) but showed significant papillary 
muscle hypertrophy.21
 
 Sequences CMR using contrast LGE can detect areas of 
abnormal myocardium.22 LGE area can be measured and quantified as 
a percentage of the total mass of the LV (Figure 8).14 In ApHCM, LGE 
patterns are usually apical and subendocardial patterns which are rare 
in other variants of HCM, without coronary artery disease (Figure 9).13
Figure 7. Upper: CMR short-axis images demonstrating massive LV 
hypertrophy with wall thickness of 31 mm. Lower: 4C and long axis 
view.19
Figure 8. Contrast-enhanced CMR with LGE in HCM. (A) Female 58 
years old asymptomatic transmural LGE vast area in the basal anterior 
septum and anterior wall. (B) Area LGE diffuse and midmyocardial 
patchy in the area of the ventricular septum in men aged 21 years. (C) 
LGE limited to the insertion area RV free wall to the anterior and 
posterior ventricular septum. 14
Figure 9. Giant precordial negative T wave and CMR of apical hypertro-
phy in relative ApHCM.13
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 T1 mapping in CMR further can help differentiation of HCM 
from the infiltrative cardiomyopathies, as they show sign and symptom 
of HCM with an increased wall thickness (Figure 10).19. Screening of 
first-degree relatives should begin at adolescence. Repeat evaluation 
every 12–18 months, and every five years until the fourth decade of 
life.19
Figure 10. CMR for differentiation of etiology of LV hypertrophy19. A) 
Pre-contrast CMR image of patients 64 yo with septum wall thickness of 
18 mm and lateral wall thickness of 14 mm, B) Post-contrast image of 
patients, confirmed amyloidosis from cardiac biopsy, demonstrates 
epicardial LGE in septum (arrows) and global subendocardial LGE 
concern for amyloidosis, C) Pre-contrast images of patients 44 yo, with 
septum wall thickness of 16 mm and 13 mm in lateral wall, D) Post-con-
trast image of patients, confirmed genetic testing that revealed 
mutation of galactosidase alpha gene, demonstrates basal inferolateral 
LGE (arrows) leading to concern for Fabry`s Disease. E) Pre-contrast 
images of patients 21 yo,  maximum wall thickness of 32 mm in septum, 
F) Post-contrast image of patients, confirmed genetic testing that 
revealed mutation of lysosomal-associated membrane protein 2 gene, 
demonstrates transmural LGE at anterior and lateral wall and mid-myo-
cardial LGE in the septum, leading to concern for Danon Disease.19
(4) Cardiac Computed Tomography (CCT)
 CCT can be used to assess the anatomy of the heart in the 
presence of inadequate echocardiographic images and has a contraindi-
cation to CMR such as on pacemakers or ICD, claustrophobia, or when 
the patient can not hold their breath for a long time.14,22,23 Technique 3D 
tomographic imaging provides excellent spatial and temporal resolu-
tion. Display in thin slices of 0.4 mm from the short axis and long-axis 
view, CCT provides complete coverage of the entire myocardium 
tomography.14,24
 
 High resolution with a contrast gives a clear picture of the 
myocardium, with the separation of white and grey (the myocardium) 
(Figure 11).14
 CCT can be used to evaluate the 3D shape, size, and 
movement of the annulus of the mitral, SAM in multiphase images and 
also evaluate the annular calcification.25 Evaluation of the coronary 
arteries identifying the presence of the stenotic lesion, as well as 
identify the presence of myocardial bridging. This technique should be 
considered in patients complaining of chest pain who have a medium to 
high probability of  CAD.14
 CCT can determine the length of the coronary arteries and 
myocardial LV, provide a clear picture of the relation of both. This 
information can be helpful in surgical myectomy procedure. Planning 
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